Posted by Michael Wonder on 16 Aug 2024
KalVista announces validation of marketing authorisation application by the EMA for sebetralstat for hereditary angioedema
15 August 2024 - KalVista Pharmaceuticals today announced that the EMA has validated the submission of a marketing authorisation application for sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.
The submission was supported by previously disclosed results, including data from the KONFIDENT phase 3 clinical trial and on0-going KONFIDENT-S open-label extension trial.
